Current and future therapeutic options for chronic hepatitis D virus infection
In the last few years there have been innovations in HDV therapy which have brought new excitement in the scientific community also considering the few therapeutic opportunities. Recently, new molecular targets have been identified, both in monotherapy and in combination with peginterferon alpha (Pe...
Saved in:
Main Authors: | Mariantonietta Pisaturo, Antonio Russo, Pierantonio Grimaldi, Salvatore Martini, Nicola Coppola |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1382017/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is Combined Bulevirtide and Pegylated Interferon Therapy for Chronic Hepatitis D Superior over Bulevirtide Monotherapy?
by: V. E. Syutkin, et al.
Published: (2020-09-01) -
Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy
by: P. O. Bogomolov, et al.
Published: (2024-12-01) -
Therapeutics in paediatric genetic diseases: current and future landscape
by: Ai Ling Koh, et al.
Published: (2023-01-01) -
Digital therapeutics in Korea: current status, challenges, and future directions – a narrative review
by: Hee Jun Shin, et al.
Published: (2025-01-01) -
Conservation Easements: Options for Preserving Current Land Uses
by: Chris Demers, et al.
Published: (2004-08-01)